Clinical trials: High Ischemic Risk
Heart Diseases, Coronary Artery Disease (CAD)
Feasibility Study SA of the Supira System for HRPCI
The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).
- Conditions
- Heart Diseases, Coronary Artery Disease (CAD), Heart Failure
- Trial name
- NCT05864248
- Testing
- Supira System
- Where
- 2 sites in Brazil
- Volunteers
- 71 people
- Sponsor
- Supira Medical
Coronary Artery Disease, Unstable Angina
Restore EF Observational Study
A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard…
- Conditions
- Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT04648306
- Testing
- Prophylactic Impella support for a non-emergent PCI
- Where
- 21 sites in United States
- Volunteers
- 406 people
- Sponsor
- Abiomed Inc.
Coronary Artery Disease
A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)
The purpose of this trial is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE Clear (NCT03647475)
- Testing
- Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
- Where
- 4 sites in United States
- Volunteers
- 752 people
- Sponsor
- Medtronic Vascular
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Carotid Artery Diseases, Stroke
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be…
- Conditions
- Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis
- Trial name
- BEACH (NCT00316108)
- Testing
- WALLSTENT® Endoprosthesis™
- Where
- 50 sites in United States
- Volunteers
- 747 people
- Sponsor
- Boston Scientific Corporation
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the…
- Trial name
- STRONG (NCT02947867)
- Testing
- aganirsen
- Volunteers
- 333 people
- Sponsor
- Gene Signal SAS
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
- Trial name
- NCT06087575
- Testing
- Supira System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Supira Medical
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Acute Ischemic Stroke
Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing Malignant Cerebral Edema (MCE)
- Trial name
- NCT05399550
- Testing
- Balovaptan
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Coronary Disease
RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime…
- Trial name
- NCT00317343
- Testing
- Bivalirudin (thrombin specific anticoagulant)
- Sponsor
- Nycomed
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
Bioflow-DAPT Study
BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study. A total of 1'948 subjects will be randomized 1:1 to receive either Orsiro Mission or Resolute Onyx.
- Trial name
- NCT04137510
- Testing
- Percutaneous coronary intervention
- Where
- 53 sites in Australia, Austria and 16 more
- Volunteers
- 1,948 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
EVOLVE Short DAPT Study
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
- Trial name
- NCT02605447
- Testing
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Where
- 110 sites in United States, Brazil and 5 more
- Volunteers
- 2,009 people
- Sponsor
- Boston Scientific Corporation
Acute Stroke, Transient Ischemic Attack
The Recurrence Study
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic.
- Trial name
- NCT03244215
- Testing
- Corneal Confocal Imaging, Magnetic resonance Imaging, Blood sample
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Coronary Artery Disease
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex…
- Trial name
- NCT04138238
- Testing
- Supraflex Cruz Sirolimus-eluting Stent
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Sahajanand Medical Technologies Limited
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Hypercholesterolemia, Coronary Arteriosclerosis
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.
- Trial name
- NCT00319449
- Testing
- Ezetimibe, Atorvastatin 10 mg
- Volunteers
- 22 people
- Sponsor
- Organon and Co
Coronary Artery Disease, Coronary Artery Disease Risk High
IVUS CHIP UPP Registry
The IVUS CHIP UPP Registry is a prospective, observational, multicenter, single-arm registry. A total of 1010 patients with complex coronary lesions will be enrolled in up to 2 years, with at least 500 men and women.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
- Trial name
- NCT06625801
- Testing
- IVUS
- Where
- 18 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- ECRI bv